Canadian Agency for Drugs and Technologies in
Canadian Agency for Drugs and Technologies in Health.
Int J Technol Assess Health Care. 2017 Jan;33(5):591-596. doi: 10.1017/S0266462317000940. Epub 2017 Nov 16.
The aim of this study was to describe an initial exploration by CADTH, Canada's pan-Canadian health technology assessment (HTA) agency, in using the INTEGRATE-HTA guidance in the production of an HTA that examined the use of both in-center and in-home dialysis modalities for the treatment of end-stage kidney disease in adults in Canada.
We outline CADTH's standard HTA production process and context and then describe the experience of the assessment team in using the INTEGRATE-HTA guidance, specifically to help structure and guide the use of a logic model, the identification of implementation issues, and the identification and examination of ethical issues. For each of the aspects, we describe and reflect on how the assessment team used the guidance, challenges that were encountered in its use, and whether and how we might address these challenges when using the INTEGRATE-HTA guidance in the future.
INTEGRATE-HTA provided detailed and helpful guidance for truly integrating wide-ranging aspects of HTA. Our agency was challenged by a steep learning curve for assessment team members, tight project timelines, and a misalignment of current HTA processes with those required to implement the guidance. Nevertheless, using the guidance initiated a dialogue about what might be needed to assess complex interventions and the potential process changes that could facilitate conducting more integrated assessments.
本研究旨在描述加拿大全加卫生技术评估机构(CADTH)在制作评估加拿大成人终末期肾病中心内和家庭内透析模式使用情况的卫生技术评估报告时,首次使用 INTEGRATE-HTA 指南。
我们概述了 CADTH 的标准卫生技术评估制作流程和背景,然后描述了评估团队在使用 INTEGRATE-HTA 指南方面的经验,特别是帮助构建和指导使用逻辑模型、确定实施问题,以及识别和检查伦理问题。对于每个方面,我们都描述并反思了评估团队如何使用该指南、在使用过程中遇到的挑战,以及我们将来是否可能以及如何解决这些挑战。
INTEGRATE-HTA 为真正整合卫生技术评估的广泛方面提供了详细和有用的指导。评估团队成员面临陡峭的学习曲线、紧张的项目时间表以及当前卫生技术评估流程与实施指南所需流程之间的不匹配,这些都给我们的机构带来了挑战。然而,使用该指南开启了关于评估复杂干预措施所需内容以及可能促进更综合评估的潜在流程变更的对话。